Welcome to our dedicated page for Chemomab Therapeutics news (Ticker: CMMB), a resource for investors and traders seeking the latest updates and insights on Chemomab Therapeutics stock.
Chemomab Therapeutics Ltd. (CMMB) generates news primarily as a clinical-stage biotechnology company developing nebokitug, a monoclonal antibody targeting the soluble protein CCL24 in fibro-inflammatory diseases. Much of the company’s news flow centers on clinical data, regulatory interactions and scientific presentations related to primary sclerosing cholangitis (PSC), a rare and progressive liver disease with no effective medical therapy other than liver transplantation in advanced cases.
Investors and observers following Chemomab news can expect detailed updates on the Phase 2 SPRING trial of nebokitug in PSC, including results from the double-blind, placebo-controlled portion and the open label extension, where patients received nebokitug for up to 48 weeks. Press releases describe safety and tolerability findings, changes in biomarkers such as ELF score, PRO-C3 and liver stiffness measurements, and analyses in subgroups with moderate or advanced fibrosis. These reports often highlight biomarker patterns that are associated with PSC disease progression and transplant-free survival.
Chemomab’s news also covers regulatory milestones, such as outcomes of End-of-Phase 2 meetings with the FDA, alignment on a single Phase 3 registration trial design using a composite of clinically relevant events, and agreements on Chemistry, Manufacturing and Controls (CMC) and nonclinical toxicology requirements. Additional announcements address Orphan Drug and Fast Track designations for nebokitug, as well as the status of an open U.S. IND for systemic sclerosis.
Another recurring theme in Chemomab’s news releases is its scientific and investor outreach. The company reports oral and poster presentations at major liver and gastroenterology meetings, including Digestive Disease Week, BSG Live, AASLD The Liver Meeting and EASL congresses, where nebokitug data and CCL24-related mechanisms are discussed. Chemomab also announces participation in rare disease summits and global investment conferences, along with corporate updates tied to quarterly financial results, patent awards and capital markets activities such as at-the-market equity offerings or ADS ratio adjustments.
Readers of the CMMB news page on Stock Titan can use this stream of clinical, regulatory and corporate announcements to track Chemomab’s progress with nebokitug in PSC and other fibro-inflammatory indications, as well as to monitor key events that may influence the company’s development plans and regulatory trajectory.
Chemomab Therapeutics (Nasdaq: CMMB) has announced a poster presentation at the International Liver Congress 2021 from June 23-26, 2021. Dr. Arnon Aharon will present findings related to the role of CCL24 in bile duct fibrosis in primary sclerosing cholangitis (PSC). This presentation, titled The peri-ductular CCL24 rich niche promotes bile duct fibrosis related liver damage in primary sclerosing cholangitis, highlights CCL24's significance in fibrosis-related diseases. Full poster access will be available on Chemomab's website post-event.
Chemomab Therapeutics Ltd (Nasdaq: CMMB) reported positive financial and operational results for Q1 2021, with a cash position of $58.2 million following a $45 million private placement. Key highlights include positive Phase Ib data for CM-101 in nonalcoholic fatty liver disease (NAFLD) and the initiation of Phase IIa trials for both primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH). The company plans to start an additional Phase II trial for Systemic Sclerosis (SSc) by year-end 2021. Net loss remained stable at $1.7 million for the quarter.
Chemomab Therapeutics Ltd (Nasdaq: CMMB) announced its CEO, Dr. Adi Mor, will present a corporate update at the Oppenheimer Virtual Rare and Orphan Disease Summit on May 21, 2021.
The event aims to share insights on Chemomab's innovative therapeutics targeting fibrosis-related diseases, particularly its monoclonal antibody CM-101, which is in clinical development for orphan diseases like Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc).
The presentation will be available online for 30 days following the event.
Chemomab Therapeutics (Nasdaq: CMMB) has started enrollment for its Phase 2a study of CM-101 aimed at treating Non-Alcoholic Steatohepatitis (NASH). CM-101, a humanized monoclonal antibody, targets CCL24 to mitigate inflammation and fibrosis. The randomized, double-blind trial will involve 40 patients and aims to evaluate CM-101's safety and anti-fibrotic effects, with results expected in the first half of 2022. This study is part of Chemomab’s broader clinical strategy, which includes ongoing trials for other fibrosis-related conditions.
Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) has appointed four new members to its Board of Directors, including Dr. Alan Moses, Dr. Claude Nicaise, Mr. Joel Maryles, and Mr. Neil Cohen. This strategic move aims to enhance clinical and regulatory expertise as the company progresses its proof-of-concept trials for CM-101, a therapeutic targeting fibrosis-related diseases. Additionally, Chemomab successfully completed a PIPE financing round, raising $45.5 million, with approximately 11.9 million ADSs outstanding on a fully diluted basis.
The Genesis Prize Foundation announced that Stan Polovets has stepped down as chairman of Anchiano Therapeutics following its merger with Chemomab Therapeutics on March 16, now trading as CMMB. During Polovets' tenure, Anchiano's stock surged 630%, outperforming many peers. The merger aims to focus on innovative therapies for inflammation and fibrosis, backed by significant investor financing. Polovets expressed gratitude for the management team's efforts, highlighting the company’s potential for further success in the biotech space.